Ayurveda-focused direct-to-consumer (D2C) brand Kapiva has raised $60 million (about ₹532 crore) in its Series D funding round, underscoring the rising investor confidence in India’s wellness and nutrition sector. The round was co-led by 360 ONE Asset and Vertex Growth, with existing backers Vertex Ventures and 3one4 Capital also participating.
Founded in 2016 by Ameve Sharma and Shrey Badhani, Kapiva has built a portfolio of more than 100 products spanning herbal supplements, gummies, capsules, and skincare offerings. The company also provides access to consultations with certified ayurvedic doctors, strengthening its position at the intersection of tradition and modern health trends.
Kapiva said the fresh infusion will be directed towards scaling research and development, expanding its manufacturing base, and stepping up marketing initiatives to reach a wider consumer base. Speaking to Inc42, cofounder Ameve Sharma revealed that a portion of the capital will be earmarked for international expansion. The brand currently operates subsidiaries in the United States, United Kingdom, and the United Arab Emirates, which together contribute 5 to 10 percent of its overall revenue.
The latest investment builds on Kapiva’s steady rise in a crowded but fast-growing market for natural nutrition. India’s ayurveda-based consumer health segment has attracted increasing investor attention over the past few years, buoyed by demand for immunity-boosting and preventive health products. Analysts suggest that with rising disposable incomes and shifting consumer preferences, the sector is poised for further growth in both domestic and global markets.
Commenting on the partnership, investors highlighted Kapiva’s ability to marry scientific validation with India’s centuries-old wellness traditions as a key differentiator. With its new war chest, the company aims to solidify its presence in India while laying stronger foundations abroad.










